Analysts expect ENDRA Life Sciences Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19,682.27 | 30,061.81 | 11,825.55 | |||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17,626.49 | 26,645.75 | 10,850.05 | |||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18,654.38 | 28,353.78 | 11,337.80 |
Analysts expect ENDRA Life Sciences Inc. to report earnings per share of -0.90 for Q3 26, against a range of -0.99 to -0.81. The most recent reported quarter, Q2 26, came in at 0.12, a 113.6% beat against the -0.89 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -9.54 | -47.06 | -1.86 | -1.71 | -2.10 | -3.26 | -1.09 | 0.12 | - | - | - | - | - | - | - | - | ||
| High Estimate | -57.05 | -4.02 | -3.67 | -1.93 | -1.77 | -1.08 | -1.17 | -0.82 | -0.81 | -0.79 | -0.78 | -0.66 | 0.08 | -0.65 | 6.54 | 2.50 | ||
| Low Estimate | -64.43 | -4.38 | -4.35 | -2.33 | -1.89 | -1.22 | -1.41 | -0.96 | -0.99 | -0.95 | -0.90 | -0.80 | 0.08 | -0.73 | 5.88 | 2.24 | ||
| Consensus Estimate | -60.74 | -4.20 | -4.01 | -2.13 | -1.83 | -1.15 | -1.29 | -0.89 | -0.90 | -0.87 | -0.84 | -0.73 | 0.08 | -0.69 | 6.21 | 2.37 |